ASH updates myelofibrosis care with expanded molecular testing, earlier transplant consultation, tailored JAK inhibitor use, anemia strategies, and aspirin guidance to reduce clot risk.
|Videos|September 28, 2016
- Hematologic Malignancies: Polycythemia Vera
- Volume 3
- Issue 3
Differences Between Polycythemia Vera and Essential Thrombocythemia
Author(s)Heinz Gisslinger, MD
Heinz Gisslinger, MD, Medical University of Vienna, discusses differences between polycythemia vera (PV) and essential thrombocythemia (ET).
Advertisement
Articles in this issue
about 10 years ago
Experts Debate Need for New Drugs to Treat Patients with PV and ETabout 10 years ago
Management of ET, PV Requires 2 Distinct Approachesabout 10 years ago
Expert Discusses Recent Developments in Polycythemia Veraabout 10 years ago
Ruxolitinib Beats Out Best Available Therapy in Polycythemia Veraabout 10 years ago
Significant Developments in Treating PVAdvertisement
Related to this article
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
2026 AACR Report Highlights Advances and New Directions in Cancer Treatment
2
Durability of PFS and OS Benefit vs. Historical Control
3
Amivantamab vs. Emerging EGFR Bispecifics in HNSCC
4
ESMO 2026 Preview: Late-Breaking Studies to Watch Across Tumor Types
5